Morningstar Quantitative research is largely based on technical factors and are highly subject to change depending on the price action. They don't officially cover PPH like they do most other large companies as part of their premium research offering, so I would not put much weight on that.
I can't comment on Goldman or any other broker's views on the company until I actually read the research report, but I wouldn't generally place much stock in their recommendations either. They tend to be myopic i.e. biased towards short-term outcomes, backward-looking and subject to drastic change depending on the newsflow coming out the companies they cover. They also have conflicts of interest if they have won or are trying to win underwriting or advisory business from the companies they cover, which are not always disclosed.